Sanovas receives patent for Multi-Balloon Catheter for Extravasated Drug Delivery

Sanovas Inc., (www.sanovas.com) a life science technology company focused on developing and commercializing next generation micro-invasive diagnostics, devices and drug delivery technologies, announced today that the United States Patent and Trademark Office issued patent # 8,540,667 for the company's Multi-Balloon Catheter for Extravasated Drug Delivery.

The Multi-Balloon Catheter for Extravasated Drug Delivery features a set of multi-lumen, multi-balloon catheters intended to locally deliver diagnostic and therapeutic agents directly to target tissues within, and adjacent to, the tubular structures of the body via the company's proprietary methods of extravasation.

The technology enables the creation of drug delivery chamber(s) within a region of the anatomy for diagnostic and therapeutic agents to be deposited. The volumetric pressure gradients of the agent(s) within the chamber(s) are modulated to perfuse the agents across the tissue membrane enabling controlled delivery of the agents directly to target tissues without violating the integrity of the vessel.

The patent is foundational to the company's NanoVas™ portfolio of Interventional Drug Delivery Catheters.  Sanovas' 'Smart Catheter' technologies, featuring its Vas Zeppelin™ and PhysioSense™ product lines, are intended to deliver entirely new systems and methods for characterizing and controlling interventional catheters to treat a myriad of disease states.

"The NanoVas™ patents will be important contributions to the advance of localized, precision therapies," stated Sanovas CEO, Larry Gerrans.  "These tools are vital to the continued growth and promise of Personalized Medicine."  

"The NanoVas Suite is a dynamic next generation drug delivery system that affords clinicians significant procedural control and that further aids their ability to mitigate the systemic toxicity associated with existing methods of drug delivery, on behalf of their patients," Gerrans added.  

Sanovas expects to commercialize the technology in coordination with its partners in Pharmaceutical and Biotechnology to meet unmet clinical needs in Pulmonology, Cardiology, Neurology and Uro-Gynecology.

SOURCE Sanovas Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
mRNA Therapeutics – Analytical and Bioanalytical Characterization